Table 1 Demographic, clinical, and surgery-related characteristics of all patients
Warfarin | Antiplatelet | Control | Total | p value | |
|---|---|---|---|---|---|
Patient | 157 (12%) | 442 (34%) | 693 (54%) | 1292 (100%) | |
Gender | |||||
Male | 59 (38%) | 115 (26%) | 159 (23%) | 333 (26%) | 0.001 |
Female | 98 (62%) | 327 (74%) | 534 (77%) | 959 (74%) | |
Age, mean ± sd | 84.76 ± 6.08 | 84.09 ± 6.61 | 83.69 ± 8.15 | 83.96 ± 7.42 | 0.3567 |
ASA score | |||||
1/2 | 0 | 13 (3%) | 69 (10%) | 82 (7%) | < 0.001 |
3 | 34 (22%) | 165 (38%) | 350 (51%) | 549 (43%) | |
4/5 | 120 (78%) | 256 (59%) | 265 (39%) | 641 (50%) | |
CCI, median (IQR, Q1 to Q3) | 6 (5–7) | 6 (4–7) | 5 (4–6) | 5 (4–7) | 0.0001 |
AO/OTA Classification | |||||
A1 | 42 (27%) | 93 (21%) | 139 (20%) | 274 (21%) | 0.47 |
A2 | 34 (22%) | 108 (25%) | 164 (24%) | 306 (24%) | |
A3 | 7 (4%) | 43 (10%) | 65 (10%) | 115 (9%) | |
B1 | 20 (13%) | 70 (16%) | 112 (16%) | 202 (16%) | |
B2 | 43 (28%) | 103 (23%) | 168 (24%) | 314 (24%) | |
B3 | 10 (6%) | 22 (5%) | 43 (6%) | 75 (6%) | |
Types of surgical procedure | |||||
Reconstruction | 63 (40%) | 178 (40%) | 282 (41%) | 523 (40%) | 0.986 |
Fixation | 94 (60%) | 264 (60%) | 411 (59%) | 769 (60%) | |
Time to surgery | |||||
< 48 h | 72 (46%) | 277 (63%) | 479 (69%) | 828 (64%) | < 0.001 |
> 48 h | 85 (54%) | 165 (37%) | 214 (31%) | 464 (36%) | |
Blood loss (ml) | |||||
Median (IQR, Q1 to Q3) | 964.04 (446.95–1652.62) | 904.105 (454.4–1486.93) | 864.3 (394.59–1349.29) | 879.02 (419.33–1446.43) | 0.0054 |
0–490 ml | 40 (26%) | 119 (27%) | 241 (35%) | 400 (31%) | 0.033 |
491–980 ml | 40 (26%) | 139 (31%) | 197 (28%) | 376 (29%) | |
981–1470 ml | 30 (19%) | 69 (16%) | 96 (14%) | 195 (15%) | |
> 1471 ml | 45 (29%) | 115 (26%) | 157 (23%) | 317 (25%) | |
Mortality | |||||
30 days | 13 (8%) | 14 (3%) | 28 (4%) | 55 (4%) | 0.0484* |
180 days | 42 (27%) | 69 (16%) | 100 (14%) | 211 (16%) | 0.0005* |
1 year | 61 (39%) | 109 (25%) | 140 (20%) | 310 (24%) | < 0.0001* |